The latest analyst coverage could presage a bad day for Arcus Biosciences, Inc. (NYSE:RCUS), with the analysts making across-the-board cuts to their statutory estimates that might leave shareholders a little shell-shocked. This report focused on revenue estimates, and it looks as though the consensus view of the business has become substantially more conservative.

Following the latest downgrade, the eleven analysts covering Arcus Biosciences provided consensus estimates of US$72m revenue in 2026, which would reflect a sizeable 70% decline on its sales over the past 12 months. Prior to the latest estimates, the analysts were forecasting revenues of US$91m in 2026. It looks like forecasts have become a fair bit less optimistic on Arcus Biosciences, given the pretty serious reduction to revenue estimates.

We'd point out that there was no major changes to their price target of US$34.36, suggesting the latest estimates were not enough to shift their view on the value of the business.

Taking a look at the bigger picture now, one of the ways we can understand these forecasts is to see how they compare to both past performance and industry growth estimates. These estimates imply that sales are expected to slow, with a forecast annualised revenue decline of 80% by the end of 2026. This indicates a significant reduction from annual growth of 3.3% over the last five years. By contrast, our data suggests that other companies (with analyst coverage) in the same industry are forecast to see their revenue grow 22% annually for the foreseeable future. It's pretty clear that Arcus Biosciences' revenues are expected to perform substantially worse than the wider industry.

The Bottom Line

The most important thing to take away is that analysts cut their revenue estimates for this year. They also expect company revenue to perform worse than the wider market. Often, one downgrade can set off a daisy-chain of cuts, especially if an industry is in decline. So we wouldn't be surprised if the market became a lot more cautious on Arcus Biosciences after today.

Want to learn more? We have estimates for Arcus Biosciences from its eleven analysts out until 2028, and you can see them free on our platform here.

Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies backed by insiders.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.